Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.71 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.65 |
| ▸ | PIK3C2G | O75747 | 2/20 | 0.65 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ACLY | P53396 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | PRKDC | P78527 | 1/20 | 0.56 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2281079 | 0.93 | PIK3C2B (0.76) | PIK3CDPIK3C2BPIK3C2GPIK3CGMAPT | |
| SCHEMBL2300612 | 0.90 | PIK3CD (0.68) | PIK3CDPIK3CGMAPTMEN1KMT2A | |
| SCHEMBL2303258 | 0.89 | PIK3CD (0.80) | PIK3CDPIK3C2BPIK3C2GPIK3CGMAPT | |
| SCHEMBL188285 | 0.87 | PIK3CD (0.81) | PIK3CDPIK3C2BPIK3C2GPIK3CGMAPT | |
| SCHEMBL188910 | 0.86 | PIK3CD (0.76) | PIK3CDPIK3C2BPIK3C2GPIK3CGMAPT | |
| SCHEMBL2303411 | 0.86 | PIK3CD (0.76) | PIK3CDPIK3C2BPIK3C2GPIK3CGMAPT | |
| SCHEMBL2300306 | 0.86 | PIK3CD (0.76) | PIK3CDPIK3C2BPIK3C2GPIK3CGMAPT | |
| SCHEMBL14050635 | 0.86 | PIK3CD (0.72) | PIK3CDPIK3C2BPIK3C2GPIK3CGMAPT | |
| SCHEMBL12292687 | 0.85 | PIK3CD (0.75) | PIK3CDPIK3C2BPIK3C2GPIK3CGMAPT | |
| SCHEMBL189820 | 0.85 | PIK3CD (0.75) | PIK3CDPIK3C2BPIK3C2GPIK3CGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | claimed |
| US-8071597-B2 | Pyrazine compounds and uses as PI3K inhibitors | MERCK SERONO SA (CH) | 2011-12-06 | — | — | US | claimed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | claimed |
| JP-2009506015-A | — | — | 2009-02-12 | — | — | JP | claimed |
| EP-1917252-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-07 | — | — | EP | claimed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | claimed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-22 | — | — | US | disclosed |
| WO-2010065923-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| EP-1917252-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | PI4KA, PIP5K1B, PDPK1 | PIK3CD 74/4885PIK3C2B 115/4885PIK3C2G 507/4885 |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | PIK3CD 2/4885PIK3C2B 17/4885PIK3C2G 46/4885 |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | PIK3CD 2/4885PIK3C2B 17/4885PIK3C2G 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.